About - JAZZ :

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Employees - 2800, CEO - Mr. Bruce C. Cozadd, Sector - Healthcare, Country - IE, Market Cap - 7.44B

Altman ZScore(max is 10): 1.52, Piotroski Score(max is 10): 7, Working Capital: $3360446000, Total Assets: $12255716000, Retained Earnings: $936232000, EBIT: 799352000, Total Liabilities: $8084649000, Revenue: $3992712000

- Current Price $122.97 - Analyst Target Price $180.72

Stats & Key Metrics
TickerJAZZ
Index-
Curent Price 122.97
Change0.10%
Market Cap7.44B
Average Volume621.70K
Income463.16M
Sales3.99B
Book Value/Share69.01
Cash/Share43.27
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees2800
Moving Avg 20days0.22%
Moving Avg 50days3.67%
Moving Avg 200days9.09%
Shares Outstanding60.44M
Earnings DateNov 06 AMC
Inst. Ownership96.94%
Key Ratios & Margins
Price/Earnings17.71
Forwad P/E5.64
PE Growth1.14
Price/Sales1.86
Price/Book1.78
Price/Cash2.84
Price/FCF6.59
Quick Ratio3.74
Current Ratio4.26
Debt/Equity1.49
Return on Assets3.95%
Return on Equity12.09%
Return on Investment4.49%
Gross Margin73.85%
Ops Margin18.49%
Profit Margin11.60%
RSI54.14
BETA(β)0.57
From 52week Low24.14%
From 52week High-8.35%
Earnings & Valuation
EPS6.94
EPS next Year21.81
EPS next Qtr5.79
EPS this Year10.39%
EPS next 5 Year15.48%
EPS past 5 Year-3.53%
Sales past 5 Year15.52%
EPS Y/Y504.09%
Sales Y/Y5.23%
EPS Q/Q65.30%
Sales Q/Q8.52%
Sales Surprise1.78%
EPS Surprise20.22%
ATR(14)3.48
Perf Week-0.06%
Perf Month3.13%
Perf Quarter12.83%
Perf Year2.71%
Perf YTD-0.02%
Target Price180.72

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer